Tolebrutininb + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis
Conditions
Myasthenia Gravis
Trial Timeline
Dec 3, 2021 → Feb 21, 2023
NCT ID
NCT05132569About Tolebrutininb + Placebo
Tolebrutininb + Placebo is a phase 3 stage product being developed by Sanofi for Myasthenia Gravis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05132569. Target conditions include Myasthenia Gravis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05132569 | Phase 3 | Terminated |
Competing Products
20 competing products in Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 77 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 77 |
| Placebo + CFZ533 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 77 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 77 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 76 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 32 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| HIZENTRA ® | CSL | Phase 2 | 51 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 32 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 76 |
| zilucoplan (RA101495) | UCB | Phase 3 | 74 |
| zilucoplan (RA101495) + Placebo | UCB | Phase 2 | 49 |